Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS

Dual endothelin-1 (ET-1) and angiotensin II (AngII) receptor antagonism with sparsentan has strong antiproteinuric actions via multiple potential mechanisms that are more pronounced, or additive, compared with current standard of care using angiotensin receptor blockers (ARBs). Considering the many...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Georgina Gyarmati, Urvi Nikhil Shroff, Audrey Izuhara, Sachin Deepak, Radko Komers, Patricia W. Bedard, Janos Peti-Peterdi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Clinical investigation 2024-10-01
Edice:	JCI Insight
Témata:	Nephrology
On-line přístup:	https://doi.org/10.1172/jci.insight.177775
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!